SURMOUNT Trial Program — Tirzepatide for Obesity

The SURMOUNT trial program is a series of Phase 3 randomized controlled trials evaluating tirzepatide (Eli Lilly, brand name Zepbound for obesity) for chronic weight management in adults with obesity or overweight with weight-related comorbidities. The results established tirzepatide as the most effective injectable weight loss medication, exceeding the efficacy benchmarks set by semaglutide 2.4 mg (Wegovy) in the STEP trials.

The dual-agonist mechanism

Tirzepatide is a synthetic peptide that simultaneously activates two incretin receptors:

• GLP-1 receptor (glucagon-like peptide-1) — the same target as semaglutide and liraglutide
• GIP receptor (glucose-dependent insulinotropic polypeptide) — a novel target not addressed by other approved agents

The dual mechanism produces greater appetite suppression, more favorable metabolic effects (including improved insulin sensitivity), and larger weight loss than GLP-1 agonism alone. GIP receptor activation also appears to improve leptin sensitivity and enhance lipid metabolism in adipose tissue.

SURMOUNT-1: Tirzepatide in adults without diabetes

Published: New England Journal of Medicine, July 2022

Design: 72-week, double-blind, randomized, placebo-controlled trial. 2,539 adults with BMI ≥30 (or ≥27 with at least one weight-related comorbidity) without diabetes.

Arms: Tirzepatide 5 mg, 10 mg, or 15 mg once weekly vs. placebo. All participants received lifestyle intervention counseling.

Key results (treatment-regimen estimand — includes all participants regardless of adherence):

DoseMean weight loss≥5% loss≥10% loss≥15% loss≥20% loss 5 mg-15.0%85%69%55%32% 10 mg-19.5%89%79%67%50% 15 mg-20.9%91%84%71%57% Placebo-3.1%35%14%6%2%

The 15 mg group achieved a mean weight reduction of 22.5% (efficacy estimand — analyzing only participants who completed treatment). For context: bariatric sleeve gastrectomy typically produces 25-30% weight loss. A pharmaceutical agent approaching surgical territory was unprecedented.

Safety: The most common adverse events were gastrointestinal — nausea (24-31%), diarrhea (17-23%), constipation (11-17%), and vomiting (6-13%). These were predominantly mild-to-moderate and concentrated during dose escalation. Discontinuation due to adverse events was 4.3-7.1% across tirzepatide groups vs. 2.6% for placebo.

SURMOUNT-2: Tirzepatide in adults with type 2 diabetes

Published: The Lancet, August 2023

Design: 72-week, double-blind, placebo-controlled. 938 adults with BMI ≥27 and type 2 diabetes.

Key results:

DoseMean weight lossMean HbA1c reduction 10 mg-13.4%-2.1% 15 mg-15.7%-2.2% Placebo-3.3%-0.5%

Weight loss was lower in the diabetes population than in SURMOUNT-1 — a pattern consistently observed across GLP-1 class drugs. HbA1c reductions were substantial, confirming the dual metabolic-weight management benefit.

SURMOUNT-3: Tirzepatide after intensive lifestyle intervention

Published: New England Journal of Medicine, August 2023

Design: Participants first completed a 12-week intensive lifestyle intervention (low-calorie diet + behavioral counseling), achieving ≥5% weight loss. They were then randomized to tirzepatide 10-15 mg or placebo for 72 weeks.

Key results: The tirzepatide group achieved an additional 18.4% weight loss beyond their initial lifestyle intervention loss, for a total of approximately 26.6% from original baseline. The placebo group regained 2.5%. This demonstrated that tirzepatide provides additive benefit on top of lifestyle intervention rather than simply substituting for behavioral change.

SURMOUNT-4: Weight maintenance after treatment

Published: The Lancet, April 2024

Design: All participants received open-label tirzepatide for 36 weeks, then were randomized to continue tirzepatide or switch to placebo for an additional 52 weeks.

Key results: During the open-label phase, participants lost a mean of 20.9%. Those who continued tirzepatide lost an additional 5.5% during the randomized phase. Those switched to placebo regained 14% of their body weight.

Interpretation: This trial definitively showed that tirzepatide's weight-loss effect requires ongoing treatment. Discontinuation leads to significant weight regain, though not full return to baseline within the 52-week observation period. This has implications for treatment duration — obesity management with tirzepatide is likely a chronic therapy, not a course-based treatment.

Context: SURMOUNT vs. STEP (semaglutide)

No head-to-head trial has directly compared tirzepatide and semaglutide for obesity (SURMOUNT-5 was designed for this). Cross-trial comparison, with the limitations that entails:

OutcomeTirzepatide 15 mg (SURMOUNT-1)Semaglutide 2.4 mg (STEP 1) Mean weight loss-20.9% (regimen) / -22.5% (efficacy)-14.9% (regimen) / -16.9% (efficacy) ≥20% weight loss57% (regimen)32% (efficacy) GI adverse eventsSimilar ratesSimilar rates Trial duration72 weeks68 weeks

The magnitude of tirzepatide's advantage — approximately 5-6 percentage points more weight loss — is consistent with the added GIP receptor agonism providing incremental benefit beyond GLP-1 alone.

Clinical significance

The SURMOUNT program shifted the obesity treatment paradigm in several ways:

1. Pharmacological therapy approaching surgical efficacy. The 20-22% mean weight loss with tirzepatide 15 mg approaches sleeve gastrectomy outcomes, previously thought achievable only through surgical intervention.
2. Dose-response relationship. Clear dose-dependent effects across 5, 10, and 15 mg doses provide prescribers with titration flexibility.
3. Chronic therapy model. SURMOUNT-4's weight regain data established that obesity pharmacotherapy with incretin agonists is maintenance-dependent — similar to antihypertensive or statin therapy rather than a curative course.
4. Dual-agonism validation. The GIP/GLP-1 dual mechanism produced better outcomes than GLP-1 alone, validating the polypharmacology approach and spurring development of next-generation multi-receptor agonists (triple agonists targeting GIP, GLP-1, and glucagon receptors are in clinical development).

Regulatory status

Based on the SURMOUNT program, tirzepatide (Zepbound) received FDA approval for chronic weight management in November 2023, at doses of 5 mg, 10 mg, and 15 mg once weekly. It was previously approved as Mounjaro for type 2 diabetes (May 2022). EMA approval for obesity followed in 2024.